1.The Differentiation of Malignant and Benign Musculoskeletal Tumors by F-18 FDG PET/CT Studies: Determination of maxSUV by Analysis of ROC Curve.
Eun Jung KONG ; Ihn Ho CHO ; Kyung Ah CHUN ; Kyu Chang WON ; Hyung Woo LEE ; Jun Heok CHOI ; Duk Seop SHIN
Nuclear Medicine and Molecular Imaging 2007;41(6):553-560
PURPOSE: We evaluated the standard uptake value (SUV) of F-18 FDG at PET/CT for differentiation of benign from malignant tumor in primary musculoskeletal tumors. MATERIALS AND METHODS: Forty-six tumors (11 benign and 12 malignant soft tissue tumors, 9 benign and 14 malignant bone tumors) were examined with F-18 FDG PET/CT (Discovery ST, GE) prior to tissue diagnosis. The maxSUV(maximum value of SUV) were calculated and compared between benign and malignant lesions. The lesion analysis was based on the transverse whole body image. The maxSUV with cutoff of 4.1 was used in distinguishing benign from malignant soft tissue tumor and 3.05 was used in bone tumor by ROC curve. RESULTS: There was a statistically significant difference in maxSUV between benign (n=11; maxSUV 3.4+/-3.2) and malignant (n=12; maxSUV 14.8+/-12.2) lesions in soft tissue tumor (p=0.001). Between benign bone tumor (n=9; maxSUV 5.4+/-4.0) and malignant bone tumor (n=14; maxSUV 7.3+/-3.2), there was not a significant difference in maxSUV. The sensitivity and specificity for differentiating malignant from benign soft tissue tumor was 83% and 91%, respectively. There were four false positive malignant bone tumor cases to include fibrous dysplasia, Langerhans-cell histiocytosis (n=2) and osteoid osteoma. Also, one false positive case of malignant soft tissue tumor was nodular fasciitis. CONCLUSION: The maxSUV was useful for differentiation of benign from malignant lesion in primary soft tissue tumors. In bone tumor, the low maxSUV correlated well with benign lesions but high maxSUV did not always mean malignancy.
Body Image
;
Bone Neoplasms
;
Diagnosis
;
Fasciitis
;
Histiocytosis, Langerhans-Cell
;
Osteoma, Osteoid
;
Positron-Emission Tomography and Computed Tomography*
;
ROC Curve*
;
Sarcoma
;
Sensitivity and Specificity
;
Soft Tissue Neoplasms
2.Risk factors of gastrointestinal bleeding for end-stage renal disease patients.
Hyung Jung OH ; Seung Jun KIM ; Sun Young PARK ; Dong Eun YOO ; Han Sung LEE ; Nam Su KU ; Ji Ae MOON ; Dong Ki KIM ; Tae Hee LEE ; Sung Jin MOON ; Seung Heok HAN ; Jeung Eun LEE ; Hoon Young CHOI ; Dae Suk HAN ; Shin Wook KANG
Korean Journal of Medicine 2007;72(6):616-624
BACKGROUDN: Gastrointestinal bleeding (GIB) is not a rare complication in end-stage renal disease (ESRD) patients on dialysis and the occurrence of GIB has also been associated with higher morbidity and mortality rates. However, reasons for the high incidence of GIB are not clear. This retrospective study was undertaken not only to analyze the clinical features of GIB but also to elucidate the independent risk factors for GIB in Korean ESRD patients. METHODS: One hundred thirty ESRD patients on dialysis at the Severance Hospital of Yonsei University College of Medicine from January 2000 to December 2005 were included in the study. The patients were divided into two groups: 65 patients with GIB (the GIB group) and 65 age-, sex-, and dialysis modality-matched patients without GIB (the C group). Clinical characteristics, medications, and laboratory findings were compared between the two groups. RESULTS: Compared to the C group, congestive heart failure (40.0% vs. 21.5%, p<0.05), coronary arterial occlusive disease (CAOD) (32.3% vs. 4.6%, p<0.005), and nonsteroidal anti-inflammatory drug (NSAID) use (18.4% vs. 1.5%, p<0.01) were significantly more common in the GIB group. The baseline serum albumin levels were significantly lower in the GIB group than in the C group (2.53+/-0.67 g/dL vs. 3.56+/-0.63 g/dL, p<0.005). Using logistic regression analysis, CAOD (OR=23.0), NSAID use (OR=12.5), and lower serum albumin levels (OR=2.9) were identified as independent risk factors for GIB (p<0.05). CONCLUSIONS: Careful attention must be paid to ESRD patients with CAOD, taking NSAIDs, or with low serum albumin levels in view of GIB.
Anti-Inflammatory Agents, Non-Steroidal
;
Arterial Occlusive Diseases
;
Dialysis
;
Heart Failure
;
Hemorrhage*
;
Humans
;
Incidence
;
Kidney Failure, Chronic*
;
Logistic Models
;
Mortality
;
Retrospective Studies
;
Risk Factors*
;
Serum Albumin